scholarly journals Nutrient-stimulated glucagon-like peptide 1 release after body-weight loss and weight maintenance in human subjects

2006 ◽  
Vol 95 (1) ◽  
pp. 160-167 ◽  
Author(s):  
Tanja C. M Adam ◽  
Manuela P. G. M. Lejeune ◽  
Margriet S. Westerterp-Plantenga
Keyword(s):  
Weight Loss ◽  
Human Subjects ◽  
Weight Maintenance ◽  
Body Weight Loss ◽  
Maintenance Period ◽  
Very Low Energy Diet ◽  
Obese Subjects ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Standard Breakfast

Glucagon-like peptide 1 (GLP-1) is a peptide hormone that is released in response to nutrient ingestion. Postprandial GLP-1 release has been reported to be attenuated in obese subjects, but reports on the effect of weight loss on GLP-1 are conflicting. The aim of the present study was to clarify the effect of a weight-loss period and a consecutive weight-maintenance period on nutrient-stimulated GLP-1 release in obese subjects. Nutrient-stimulated (standard breakfast; 1·9MJ) GLP-1 release was investigated in thirty-two obese subjects on three occasions: before weight loss (T1) (BMI 30·0 (sd 2·5) kg/m2); after a 6-week very-low-energy diet (VLED) (T2) (BMI 27·6 (sd 2·3) kg/m2); after a 3-month weight-maintenance period (T3) (BMI 27·9 (sd 2·3) kg/m2). At each occasion, following a fasting blood sample the test meal was fed and blood was drawn every 30min for 2h relative to ingestion in order to determine plasma GLP-1, insulin, glucose and NEFA concentrations. Subjects lost 7 (sd 3·4) kg during the VLED (P<0·0001) and regained 1 (sd 3·2) kg during the weight-maintenance period (NS). The area under the curve for nutrient-stimulated plasma GLP-1 (pmol/l×h) was significantly decreased (P=0·01) at T2 (6·8 (sd 1)) compared with T1 (12·8 (sd 2·9)) and T3 (11·1 (sd 1·5)). Since we found a rebound of concentrations after a weight-maintenance period, decrease after weight loss seems to be transient and possibly due to a negative energy balance.

scholarly journals Effects of green tea on weight maintenance after body-weight loss

2004 ◽  
Vol 91 (3) ◽  
pp. 431-437 ◽  
Author(s):  
Eva M. R. Kovacs ◽  
Manuela P. G. M. Lejeune ◽  
Ilse Nijs ◽  
Margriet S. Westerterp-Plantenga
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Green Tea ◽  
Weight Regain ◽  
Weight Maintenance ◽  
Epigallocatechin Gallate ◽  
Body Weight Loss ◽  
Caffeine Consumption ◽  
Very Low Energy Diet ◽  
Obese Subjects

The present study was conducted to investigate whether green tea may improve weight maintenance by preventing or limiting weight regain after weight loss of 5 to 10% in overweight and moderately obese subjects. The study had a randomised, parallel, placebo-controlled design. A total of 104 overweight and moderately obese male and female subjects (age 18–60 years; BMI 25–35kg/m2) participated. The study consisted of a very-low-energy diet intervention (VLED; 2·1MJ/d) of 4 weeks followed by a weight-maintenance period of 13 weeks in which the subjects received green tea or placebo. The green tea contained caffeine (104mg/d) and catechins (573mg/d, of which 323mg was epigallocatechin gallate). Subjects lost 6·4 (sd 1·9) kg or 7·5 (sd 2·2) % of their original body weight during the VLED (P<0·001). Body-weight regain was not significantly different between the green tea and the placebo group (30·5 (sd 61·8) % and 19·7 (sd 56·9)%, respectively). In the green tea treatment, habitual high caffeine consumption was associated with a higher weight regain compared with habitual low caffeine consumption (39 (sd 17) and 16 (sd 11)%, respectively; P<0·05). We conclude that weight maintenance after 7·5% body-weight loss was not affected by green tea treatment and that habitual caffeine consumption affected weight maintenance in the green tea treatment.

scholarly journals Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects

2005 ◽  
Vol 93 (6) ◽  
pp. 845-851 ◽  
Author(s):  
Tanja C. M. Adam ◽  
Margriet S. Westerterp-Plantenga
Keyword(s):  
Fatty Acid ◽  
Guar Gum ◽  
Normal Weight ◽  
Satiety Hormone ◽  
Physiological Feedback ◽  
Obese Subjects ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Standard Breakfast ◽  
Analogue Scales

The present study was conducted to assess whether glucagon-like peptide-1 (GLP-1) release and appetite after a breakfast with or without an additional galactose/guar gum stimulation is different in normal-weight compared with overweight/obese subjects. Twenty-eight overweight/obese (BMI 30·3 (sd 2·7) kg/m2; age 44·3 (sd 9·7) years) and thirty normal-weight subjects (BMI 22·8 (sd 1·4), age 31·5 (sd12·8) years) participated in a crossover study. Fasting and postprandial plasma GLP-1, insulin, glucose and free fatty acid concentrations were measured in response to either a galactose (50 g)/guar gum (2·5 g) load (836 kJ) and a standard breakfast (1·9 MJ; GG), or water (250 ml) and the standard breakfast (W) every 30 min relative to the ingestion for 120 min. Appetite was assessed using 100 mm visual analogue scales. GLP-1 concentrations were significantly increased after GG at 30 and 60 min compared with W in both groups. Plasma GLP-1 concentrations in the W condition were higher in normal-weight than overweight/obese subjects (P=0·03). No difference was observed in the GG condition between groups. Satiety was increased in normal-weight compared with overweight/obese subjects in the GG condition at 30 (P=0·02) and 60 (P=0·04) min. We conclude that after a standard breakfast with water, GLP-1 release was lower in the overweight/obese than the normal-weight subjects. However, postprandial GLP-1 release in overweight/obese subjects was no different from that of normal-weight subjects when galactose/guar gum was added to the breakfast. The latter was not mirrored by subjective feelings of satiety. Disturbed perception of the physiological feedback of a satiety hormone rather than disturbed feedback itself might contribute to obesity.

scholarly journals Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity

2019 ◽  
Vol 15 (4) ◽  
pp. 22-30 ◽  
Author(s):  
Ekaterina V. Tikhonenko ◽  
Alina Y. Babenko ◽  
Evgeny V. Shlyakhto
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Visceral Obesity ◽  
Metabolic Parameters ◽  
Response Predictors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Standard Breakfast

Background: Type 2 diabetes mellitus (DM2), which mainly develops from visceral obesity, is a socially significant disease. Reduction of losses from DM2 is a priority in modern medicine development. Glucagon-like peptide-1 receptor agonists (aGLP-1) present one of few groups of antidiabetic drugs that allows to reduce not only glycemia, but also weight in DM2. Taking into account predictors of response to the therapy will allow to reach trearment targets with the highest probability, maintaining a safety of treatment, to optimize recommendations for administration of aGPP-1 as much as possible. Aims: To assess dynamics of metabolic parameters, to identify predictors of reduction in blood glucose, body weight and other metabolic parameters on aGLP-1 therapy in patients with DM2 with body mass index (BMI) 35 kg/m2. Materials and methods: The study involved 33 patients (10 men, 23 women), who had been treated with aGLP-1, the observation period for 24 weeks was planned. 3 patients terminated the participation before the appointed time (1 due to pancreatitis development 2 due to the lack of financial opportunity to purchase the drug). So, 30 patients (10 men, 20 women) were included in the final analysis. Examination consisted of the survey, physical examination with measurement of anthropometric, clinical parameters, filling questionnaires. Data were evaluated at baseline and after 24 weeks of treatment. Results: The study found that patients who achieved weight loss 5% initially had higher BMI (p = 0.028), lower GLP-1 (p = 0.036), had lower level of ghrelin after standard breakfast test (p = 0.022). There was trend (p = 0.071) to greater decrease in BMI in patients with restrictive type of eating behavior compared to patients who had a mixed type. More pronounced decrease in glycemia was noted in patients who had higher fasting plasma glucose level at inclusion (p = 0.001). Dynamics of HbA1c was better in patients with initially higher GLP-1 (p = 0.016) and higher levels of glycemia (p = 0.001). Also, we revealed the statistically significant decrease in triglycerides level, blood pressure by end of the treatment period. Conclusions: Results indicate the different predictors for reduction in weight, glycemia and blood pressure on aGLP-1 therapy. In addition to the metabolic parameters, level of orexigenic and anorexigenic hormones and psycho-social characteristics of patients help to estimate an expected effect of aGLP-1 therapy. When being identifying, the predictors of weight loss and the predictors of carbohydrate metabolism compensation should be studied separately. Identification of response predictors is necessary to optimize indications for this group of drugs administration in DM2.

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

Metabolism ◽  
2000 ◽  
Vol 49 (6) ◽  
pp. 709-717 ◽  
Author(s):  
Fernando Rodriquez de Fonseca ◽  
Miguel Navarro ◽  
Elvira Alvarez ◽  
Isabel Roncero ◽  
Julie A. Chowen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Body Weight Loss ◽  
Central Effects ◽  
Receptor Agonists ◽  
Obese Rats ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Decreased Basal Levels of Glucagon-Like Peptide-1 after Weight Loss in Obese Subjects

2007 ◽  
Vol 51 (2) ◽  
pp. 134-138 ◽  
Author(s):  
D.A. de Luis ◽  
M. Gonzalez Sagrado ◽  
R. Conde ◽  
R. Aller ◽  
O. Izaola
Keyword(s):  
Weight Loss ◽  
Obese Subjects ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity.

2018 ◽  
Vol 96 (8) ◽  
pp. 746-753
Author(s):  
E. V. Tikhonenko ◽  
A. G. Arkhipova ◽  
A. Y. Babenko ◽  
E. V. Shlyakhto
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Weight Loss ◽  
Visceral Obesity ◽  
Response To Therapy ◽  
Metabolic Parameters ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Standard Breakfast

Diabetes type 2 (CD2), which develops mainly against visceral obesity, is socially significant disease, reduction of losses from which is priority in development of modern medicine. Glucagon-like peptide-1 receptor agonists (aGPP-1) is one of few groups of antidiabetic drugs that allows to reduce not only glycemia, but also weight with CD2. Taking into account predictors of response to therapy will allow highest probability to reach targets while maintaining safety of treatment, optimize recommendations for appointment of aGPP-1 as much as possible. Aims: to assess dynamics of metabolic parameters, to determine predictors of reduction in blood glucose, body weight and other metabolic parameters in AGPP-1 therapy in patients with type 2 diabetes with body mass index (BMI) >35 kg/m. Material and methods. Study involved 33 patients (10 men, 23 women) who had been treated with aGPP-1, planned period of observation for 24 weeks. Early termination ofparticipation of 3 patients (1 - due to development ofpancreatitis, 2 - due to lack of financial opportunity to purchase the drug). Accordingly, 30 patients (10 men, 20 women) were included in final analysis. Examination consisted of survey, physical examination with measurement of anthropometric, clinical parameters, filling questionnaires. Data were evaluated initially and after 24 weeks of treatment. Results. Study found that patients who achieved weight loss > 5% initially had higher BMI (p = 0.028), lower GLP-1 (p = 0.036), had lower level of ghrelin after sample with standard breakfast (p = 0.022). There was trend (p = 0.071) to greater decrease in BMI in patients with restrictive type of eating behavior compared to patients who had mixed type. More pronounced decrease in glycemia was noted in patients who had higher fasting plasma glucose level at inclusion (p = 0.001). Dynamics of HbA1C was better in patients with initially higher GLP-1 (p = 0.016) and higher levels of glycemia (p = 0.001). Also, in examined patients, there was statistically significant decrease in level of triglycerides, blood pressure by end of treatment period. Conclusions. Results indicate that there are different predictors for weight loss, glycemia and blood pressure in aGPP-1 therapy. In addition to metabolic parameters, level of orexigenic and anorexigenic hormones and psycho-social characteristics ofpatients help to estimate expected effect of therapy for ARP1. When predictors are identified, predictors of weight loss and carbohydrate metabolism compensation should be studied separately. Identification of response predictors is necessary to optimize indications for prescribing this group of drugs with CD2.

Sign in / Sign up

Export Citation Format

Share Document